Hims & Hers launches perimenopause and menopause care on platform

SAN FRANCISCO - Hims & Hers Health, Inc. (NYSE:HIMS) announced Wednesday the addition of perimenopause and menopause treatment options to its women’s health platform. The digital health company now offers personalized treatment plans for women experiencing these life stages.

The new specialty allows eligible customers to access prescription medications including estradiol and progesterone in various forms such as pills, patches, and creams. These treatments aim to address symptoms like hot flashes, night sweats, and sleep disturbances.

"Women have been navigating an outdated healthcare system that wasn’t designed for them for too long," said Dr. Jessica Shepherd, Chief Medical Officer of Hers, in the press release. "Hers was built to serve every woman on her terms."

The company noted that approximately 1.3 million women in the U.S. experience menopause annually, yet only about 30% of OB/GYN residency programs provide formal menopause training.

Each treatment plan is overseen by independent licensed providers trained specifically in perimenopause and menopause care. The company plans to expand its treatment options in 2026.

Hers currently serves over half a million subscribers and projects reaching $1 billion in annual revenue by the end of 2026, according to the announcement. The company’s strong momentum is reflected in its impressive 137% return over the past year. InvestingPro data reveals 16 additional key insights about HIMS’s valuation and growth prospects, available in the comprehensive Pro Research Report.

The perimenopause and menopause specialty joins the company’s existing women’s health offerings on the Hers platform. Treatment availability varies by state and requires prescription authorization following online provider consultation. With a gross profit margin of 76% and strong cash flows, the company appears well-positioned to support its expansion in the healthcare sector.

In other recent news, Hims & Hers Health, Inc. has announced an expansion into menopause and perimenopause treatments, aiming to tap into a market with approximately 1.3 million women in the United States experiencing menopause annually. This move is seen as a significant opportunity for the company to scale its platform. Meanwhile, BofA Securities has maintained its Underperform rating on Hims & Hers, keeping a price target of $28.00. The firm anticipates that the company’s third-quarter revenue will align with consensus estimates but expresses concern over the 16% year-over-year decline in orders reported for September. Additionally, a survey conducted by Hims & Hers revealed that 94% of customers rated their telehealth experience as equal to or better than traditional in-person care. This insight is part of a white paper titled "Understanding Hims & Hers Approach to Clinical Excellence, Quality, and Safety," based on feedback from nearly 2,400 customers. These developments come as the company navigates a challenging sales environment while attempting to grow its service offerings.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.